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Abstract
Amyloidosis comprises a group of protein-folding disorders in which extracellular
deposits  share  unique  Congo  red  staining  properties  and  fibrillary  ultrastructural
appearance. These fibrillary deposits ultimately cause tissue destruction and progres‐
sive disease. Amyloidosis can be either systemic affecting multiple organs or local‐
ized.  Renal  involvement  by  amyloidosis  (amyloid  nephropathy)  is  a  frequent
manifestation of systemic amyloidosis. Immunofluorescence, immunohistochemistry
(IHC), and more recently laser microdissection and mass spectrometry (LMD/MS) are
important techniques in typing of amyloid nephropathy. This in-depth review discusses
practical diagnostic approach and pathogenesis of amyloid nephropathy and includes
discussion of treatment and prognosis.
Keywords: amyloid nephropathy, light microscopy, immunofluorescence, immuno‐
histochemistry, electron microscopy, proteomics
1. Introduction
Amyloidosis comprises a group of protein-folding disorders in which extracellular deposits
share unique Congo red staining properties and fibrillary ultrastructural appearance [1]. These
fibrillary  deposits  ultimately  cause  tissue  destruction  and  progressive  disease.  Amyloid
consists of randomly arranged, nonbranching fibrils that measure 8–12 nm in diameter [1].
Amyloidosis is a rare group of diseases, with an estimated prevalence of 1: 60,000 [2]. In the
USA and Europe, amyloidosis derived from immunoglobulin (Ig) light chain (AL) secon‐
dary to plasma cell dyscrasia is the most prevalent form, followed by reactive AA amyloido‐
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sis (AA) derived from serum amyloid A (SAA), which is typically associated with chronic
inflammatory conditions. This is in contrast to developing countries in Africa and Middle East
of Asia, where AA is much more common than AL [3–5]. Leukocyte chemotactic factor 2
amyloidosis (ALECT2), derived from leukocyte chemotactic factor 2 protein (LECT2), is newly
recognized as a common type of amyloid, with unknown etiology [6]. Familial amyloidosis is
diagnosed with increasing frequency with the use of new immunohistochemical studies and
mass  spectrometry  [7].  Amyloidosis  can  be  either  systemic  affecting  multiple  organs  or
localized.  Renal  disease  is  a  frequent  manifestation  of  systemic  amyloidosis  with  AL,
previously called primary amyloidosis, the most common type involving the kidney.
2. Amyloid nephropathy
The types of amyloid are categorized by the chemical composition of the proteins. There are
more than 25 precursor proteins identified as major proteins in amyloid deposition so far. A
large study from the Mayo clinic [8] showed that among 474 patients with amyloid diag‐
nosed by renal biopsies between 2007 and 2011, Ig-related amyloidosis (AIg) was the most
common form involving the kidney (85.9%), followed by AA (7.0%), ALECT2 (2.7%), fibrino‐
gen A α chain amyloidosis (AFib) (1.3%), apolipoprotein AI amyloidosis (AApo AI), apolipo‐
protein AII amyloidosis (AApo AII), or apolipoprotein AIV amyloidosis (AApo AIV) (0.6%),
AA/light and heavy chain amyloidosis (AHL) (0.2%), and unclassified amyloidosis (2.3%). AIg
in most cases is derived from fragments of monoclonal light-chain protein (AL). However, in
rare cases, AIg is derived from truncated Ig heavy chain and light chain (AHL) or isolated
truncated Ig heavy chain [8, 9]. AIg is associated with B-cell lymphoproliferative disorders
including multiple myeloma and plasma cell dyscrasia, B-cell lymphoma, and Walden‐
ström’s macroglobulinemia [8]. In contrast, AA is characterized by tissue deposition of serum
amyloid A protein, which is derived from an acute-phase reactant protein synthesized by the
liver [10]. AA is seen in conditions associated with chronic inflammation including rheuma‐
toid arthritis, ankylosing spondylitis, chronic draining infections (i.e., osteomyelitis, chronic
skin infections including decubitus ulcers, bronchiectasis, and chronic sinusitis), Crohn
disease, tuberculosis, and familial Mediterranean fever (FMF) [10]. Familial amyloidosis
comprises another group of amyloid that is now being diagnosed more frequently and includes
amyloid derived from transthyretins (TTR) [11], fibrinogen [12], lysozyme (Lys) [13], gelso‐
lin (Gel) [14], Apo AI [15], Apo AII [16], and Apo AIV [17]. ALECT2 nephropathy was first
described in 2008 [6, 18]. LECT2 is a chemotactic factor for neutrophils and has other physio‐
logic functions, including cell proliferation, immunomodulation, repair after injury, tumor
suppression, and glucose metabolism [6, 18]. ALECT2 is now the third most common type of
amyloid nephropathy in the USA and accounts for 2.5–2.7% of amyloid nephropathy cases [6,
18]. ALECT2 involves mainly in the kidney and liver but rarely involve other organs such as
spleen, adrenal, and myocardium [6, 18]. Type and precursor protein of amyloid nephrop‐
athy are summarized in Table 1.
Exploring New Findings on Amyloidosis282
Amyloid precursor protein Amyloid type
Restricted light chain (lambda or kappa) AL
Ig heavy chain AH
Ig heavy and light chain AHL
Serum amyloid associated protein (SAA) AA
Leukocyte chemotactic factor type 2 (LECT2) ALECT2
Fibrinogen A-α chain AFib
Transthyretin (TTR) ATTR
Apolipoprotein A-I AApo AI
Apolipoprotein A-II AApo AII
Apolipoprotein A-IV AApo AIV
Gelsolin AGel
Lysozyme ALys
Table 1. Type and precursor protein of amyloid nephropathy.
3. Clinical features
The clinical features of patients with amyloidosis vary, depending on the varying predilec‐
tion of different types of amyloid for specific organ involvement. As described above, renal
involvement is a frequent manifestation of amyloidosis, more often in AIg nephropathy, AA
nephropathy, and some forms of familial amyloidosis [10, 12]. Amyloid nephropathy of any
type is more common in men than in women [8]. A large retrospective review of patients with
amyloidosis evaluated from 1981 to 1992 at the Mayo Clinic in Rochester, Minnesota, re‐
vealed 1315 patients, including 918 patients with AL amyloidosis (69.8%). Of these, 474 patients
had new-onset AL amyloidosis, including 69% men and 31% women with median age of
64 years [19]. At the time of diagnosis, about 17% of AL patients had either multiple myelo‐
ma or smoldering myeloma and about 16% had history of monoclonal gammopathy of
undetermined significance (MGUS). On presentation, about 51% of men and 47% of women
had renal failure, and about 73% of patients had proteinuria. The median 24-h urine protein
was 1.2 g/d and in the patients with full nephrotic syndrome, about a quarter of patients, the
mean 24-h urine protein excretion was 7.0 g/d. Serum protein electrophoresis (SPEP) re‐
vealed a monoclonal protein in about 48% of patients and when serum immunoelectrophore‐
sis was tested the percentage increased to about 72%. A monoclonal light chain was detected
in about 73% of the patients by urine immunoelectrophoresis or immunofixation, including
about 68% with lambda and about 32% with kappa. Overall, about 89% of the patients with
AL amyloidosis showed a serum or urine monoclonal spike (M spike).
Patients with AA nephropathy usually present at younger age than AL patients, whereas
ALECT2 is more common in older patients. ALECT2 nephropathy mainly affects patients of
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Hispanic or Mexican origin and rarely affects Caucasian patients, whereas AL and AA do not
show evident ethnic differences [6, 18]. As in AL amyloid, proteinuria is also the most common
clinical presentation in AA, ALECT2, and familial amyloid nephropathy [8]. Extrarenal
manifestations of amyloidosis include congestive heart failure caused by myocardial infiltra‐
tion by amyloid, orthostatic hypotension, bladder dysfunction, and dysesthesias caused by
amyloid infiltration into autonomic and peripheral nerves, lymphadenopathy, hepatomega‐
ly, splenomegaly, and macroglossia [18, 20]. The treatment and prognosis of amyloid nephr‐
opathy will be discussed below.
4. Molecular mechanisms and pathogenesis of amyloidosis
Misfolding of extracellular proteins has a prominent role in the molecular mechanisms and
pathogenesis of amyloidosis [21, 22]. The misfolded proteins are highly prone to self-aggre‐
gation. There are different mechanisms of formation of pathologic misfolded proteins [22]. The
first is based on intrinsic propensity of the protein to assume pathologic conformation, which
becomes more evident with aging. Examples of these mechanisms are evident when molecu‐
larly normal transthyretin misfolds in patients with senile systemic amyloidosis [22]. The
second way is due to alteration of the normal protein sequence, as seen with the replace‐
ment of a single amino acid in protein, e.g., in AL and familial amyloidosis [22]. Only a small
portion of Ig light chains is amyloidogenic; thus, AL nephropathy occurs only in about 12–15%
of the patients with multiple myeloma [23]. The amyloid fibrils in amyloid nephropathy consist
of either intact light chains containing the variable and constant domains or solely the variable
domains, which contains the N-terminus portion of the light-chain molecule. The VλVI
subgroup of the light chain preferentially leads to amyloid formation in patients with AL
nephropathy [23, 24]. Therefore, it appears that germ line sequences, which enhanced near the
N-terminus of the lambda light chain and in the VλVI of the light chain may be prone to
mutations that generate amyloidogenic light chains. These altered proteins lead to destabili‐
zation of light chain and increase the likelihood of fibril formation [25]. In familial amyloido‐
sis, such as Transthyretin-related hereditary amyloidosis (ATTR) and Lysozyme-related
amyloidosis (ALys), the substitution of a single amino acid transforms a normal protein into
an amyloidogenic protein [26, 27]. The unstable protein produced by amino acid substitu‐
tion may allow the protein to precipitate when stimulated by the local physicochemical milieu,
such as local surface pH, electric field, and hydration forces on the cellular surfaces [22]. A
third mechanism contributing to amyloid formation is proteolytic remodeling of the protein
precursor, as seen in Alzheimer’s disease, in which the fibrils are composed of proteolytic
fragments of 39–43 residues derived from 753-residue β-amyloid precursor protein (APP) [28].
This type of amyloid does not affect the kidney. In addition, excessive concentration of
amyloidogenic protein due to unregulated production of high local concentration can promote
amyloidosis [29]. When the protein precursor reaches a critical point of local concentration, it
triggers fibril formation. This mechanism is enhanced further by environmental physicochem‐
ical factors and interaction with extracellular matrix. This mechanism may occur in AA
amyloidosis associated with chronic inflammatory conditions or familial Mediterranean
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fever [30]. The excessive concentration of amyloidogenic protein may also be caused by
decrease in clearance from the body; e.g., Beta-2 microglobulin associated amyloidosis (Aβ2M)
develops in end-stage renal disease patients who received long-term dialysis because of
ineffective clearance of β2M from circulation during dialysis or due to inability of the body to
destroy the accumulation by natural mechanism [31]. Regardless of mechanism of misfold‐
ing, the misfolded proteins are prone to self-aggregate, generating protofilaments that interact
to form fibrils [22].
In AL nephropathy, amyloid formation in the kidney first begins in the mesangium. The
specific uptake of light-chain protein by mesangial cells underlies the predominant kidney
tropism and is an important step in amyloid fibril formation. There are several factors that
might promote or decelerate amyloid deposition in glomeruli, including the negative ion
charge and the high concentration of glycosaminoglycan of the glomerular basement mem‐
branes with the presence of enzyme proteases that could render protein amyloidogenic [32].
Mesangial cells are modified smooth muscle cells, which have phagocytic activity [33]. Upon
interaction with light-chain proteins, the light-chain proteins are avidly internalized and
delivered to the primary lysosomes where the amyloid fibrils are primarily formed [34].
During this process, the mesangial cells transform into a macrophage phenotype with
prominent primary lysosomes, making them more capable of processing of internalized
amyloidogenic light-chain proteins and fibril formation [34]. The amyloid deposition within
the mesangium further stimulates metalloproteinase enzymes, causing mesangial matrix
degradation, inhibiting transforming growth factor β (TGF-β) and thus impairing mesangial
matrix repair [33, 35] and increasing apoptosis, finally leading to significant mesangiolysis and
replacement of the mesangial area by amyloid deposits [36]. These changes result in the
absence of mesangial argyrophilia and significant mesangial cell deletion in the advanced stage
of glomerular amyloidosis [34].
LECT2 has multiple functions including as a cytokine involved in chemotaxis of neutrophils
and a growth factor involved in cell proliferation and regulation of repair after injury,
immunomodulation, tumor suppression, and glucose metabolism [37]. The pathogenesis of
ALECT2 is not well understood, but may be due to increased synthesis of LECT2 by hepato‐
cytes or secondary to hepatocellular damage or involve interference, possible due to genetic
defect, in the LECT2 catabolism or LECT2 transportation, which may give rise to local LECT2
tissue concentration and finally lead to amyloid fibril formation [6, 18, 37].
The normal plasma protein serum amyloid P component (SAP), a glycoprotein that belongs
to the pentraxin family, independently binds to fibrils in all types of amyloid and contrib‐
utes to pathogenesis of amyloidosis [38]. SAP is highly protected against proteolysis, and a
binding of SAP to amyloid fibrils in vitro protect them from proteolytic enzymes and
degradation by phagocytic cells. Moreover, SAP is a stubborn glycoprotein that can persist
within human amyloid deposits for prolonged periods and is completely unmodified with
respect to circulating SAP [38]. It is suggested that SAP may contribute to the failure to clear
amyloid deposition in vivo, leading to tissue architecture destruction and organ dysfunction.
Furthermore, amyloid can be deposited in multiple organs, and this tendency might depend
on several physicochemical factors, such as high concentration of local protein, low pH,
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presence of proteolytic processing, and seeding of protofilaments [22]. The amyloid deposits
cause tissue architecture destruction, presumed to cause organ dysfunction [22]. Further‐
more, the amyloidogenic precursor proteins, folding intermediates, and protofilaments have
toxicities independent of the amyloid deposits and these toxicities can also contribute to
disease manifestations [39].
5. Gross findings
Postmortem examination of patients with amyloidosis generally shows enlarged kidneys,
unlike other causes of chronic kidney disease (CKD) where kidneys are small and shrunken.
In addition, cut surfaces of kidney in patients with amyloid nephropathy are pale, firm, waxy,
and flat [38] (Figure 1a), which are different from the normal kidney or the kidney in the
patients with CKD (Figure 1b), which bulges slightly causing in slight curvature of the cut
surfaces.
Figure 1. At autopsy of a patient with amyloid nephropathy, the kidney is enlarged and pale with waxy and flat cut
surface (a, arrow), which is different from the kidney in a patient with chronic kidney disease with a simple cyst,
which bulges slightly (arrow) resulting in slight curvature of the cut surfaces (b).
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6. Histologic diagnosis and identification of amyloid
6.1. Light microscopy
The light microscopic (LM) findings of amyloidosis are identical regardless of the type of
amyloid. Glomerular amyloid deposition begins with progressive accumulation of acellular
amorphous eosinophilic material (cotton candy appearance) on hematoxylin and eosin (H&E)-
stained sections (Figure 2) that appear pale with the periodic acid Schiff (PAS) stain
(Figure 3a and b). In the advanced stage, the mesangial matrix is extensively replaced by
acellular amorphous material exhibiting uniform expansion with compression of the capilla‐
ry spaces and occasional nodular formation, resembling diabetic nephropathy or monoclo‐
nal immunoglobulin deposition disease. The nodular pattern is seen more frequently in AA
nephropathy. The amyloid deposits are paler on PAS stain than the Kimmelstiel-Wilson
nodules in diabetic nephropathy, or deposits in light-chain deposition disease or fibrillary
glomerulonephritis. Further, fibrillary glomerulonephritis typically is proliferative, with
increased cellularity seen by light microscopy. The amyloid deposits stain weakly or are
negative with Jones methenamine silver stain (JMS) and appear as negative defects in the
expanded mesangium and thick glomerular basement membranes (Figure 4a and b).
Occasionally, there is a focal parallel alignment of amyloid fibrils in the subepithelial zone that
results in focal capillary wall spikes, which are best visualized by JMS (Figure 5). These spikes
are focal, closely clustered, and longer than the typical spikes of membranous nephropathy.
The focal clusters of spikes may resemble feathers, so-called feathery spikes. Amyloid feathery
spikes are more common in AL than AA or familial amyloidosis [7]. Rarely crescent forma‐
tion can be seen in both AA and AL [7], indicating glomerular basement membrane breaks,
the injury that triggers crescent formation, can occur. Vascular involvement by amyloidosis is
common, frequently involving arteriolar walls, followed by arteries, peritubular capillaries,
and veins. In rare cases, particularly in AL or in ATTR nephropathy, the vessels are the only
part in the kidney where amyloid is demonstrated. Interstitial amyloid deposition is seen in
about 50% of cases but is present in most cases of ALECT2 nephropathy (Figure 6). Glomer‐
ular involvement is not extensive in ALECT2 and apolipoprotein AI (AApo AI/), AII
(AApoAII), and AIV (AApoAIV) nephropathy in comparison with other types of amyloid. In
addition, the histology of AFib nephropathy is very characteristic, showing glomerular
enlargement with near-total replacement of the glomeruli by amyloid, with little or no vascular
or interstitial involvement [10]. Special IF and immunohistochemistry (IHC) together with
mass spectrometry analyses are typically used to identify the type of amyloid (see below).
However, potassium permanganate treatment prior to Congo red staining has been used to
distinguish between AA and AL nephropathy: after this treatment, birefringent Congo red
staining is lost by AA but retained by AL. This technique is not commonly used and has been
replaced by more specific SAA immunohistochemistry (IHC).
Amyloid is defined by its tinctorial characteristics, which include Congo red positivity
(orange, salmon pink, or pale rose staining, Figure 7). The Congo red stain gives apple-green
or traffic light green birefringence under polarized light (Figure 8). The mesangial expan‐
sion can be focal and may be segmental, global, or even nodular. However, the degree of
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proteinuria does not correlate with the amount of amyloid deposition; as a result, cases with
early amyloidosis with scant and segmental amyloid deposition can be mistakenly diag‐
nosed as minimal change disease if no Congo red stain, immunofluorescence (IF) and electron
microscopy (EM) is performed. To demonstrate small amounts of amyloid deposits in tissue
sections, it is recommended that the sections be cut thicker than normal (6 μm, instead of
customary 2 μm) [40]. Proper detection of apple green birefringence depends on the intensi‐
ty of the transmitted light and, thus, a strong light source is strongly suggested to maximize
results. In early amyloidosis with small amounts of amyloid, it might be difficult to demon‐
strate Congo red positivity. Therefore, an alternative way of identifying a small amount of
amyloid deposits by Congo red stain is to place the stained section under fluorescent light;
amyloid then is bright red [41] (Figure 9). Of note, false positivity may result from overstain‐
ing, and this technique is not specific for amyloid. Thus, amyloid must be confirmed by apple
green polarization, immunofluorescence, IHC, and/or electron microscopy. An alternative
option to demonstrate amyloid deposits in cases with no paraffin embedded tissue available
is to perform Congo red stain on frozen tissue (Figure 10). This technique is more sensitive
than a Congo red stain performed on paraffin embedded tissue from our experience. Of note,
positive controls should then, of course, also be performed on frozen tissues.
Figure 2. In amyloid nephropathy, there is extensive mesangial expansion by amorphous eosinophilic acellular materi‐
al (“cotton candy” appearance), which segmentally extends to the glomerular capillary loops (H&E stain, original mag‐
nification ×400).
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Figure 3. In amyloid nephropathy (a), mesangial areas are globally expanded by weak PAS positive acellular deposits
(arrow) in comparison to a glomerulus (b) in normal kidney biopsy (PAS stain, original magnification ×400).
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Figure 4. In amyloid nephropathy (a), mesangial amyloid deposits are nonargyrophilic (silver negative, arrow) in com‐
parison with a glomerulus in the normal kidney biopsy (silver positive, b) (JMS stain, original magnification ×400).
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Figure 5. Feathery spikes (arrow) are a characteristic features of amyloid nephropathy seen on JMS, and are seen more
frequently in AIg than other forms of amyloid nephropathy (JMS stain, original magnification ×400).
Figure 6. ALECT2 amyloid nephropathy with intense interstitial amyloid (arrow) seen by immunohistochemistry
staining (anti-LECT2 IHC, original magnification ×400).
Amyloid Nephropathy: A Practical Diagnostic Approach and Review on Pathogenesis
http://dx.doi.org/10.5772/64083
291
Figure 7. Congo red positive mesangial deposits of amyloid with orange or salmon pink staining (Congo red stain,
original magnification ×400).
Figure 8. Amyloid deposits with characteristic apple green birefringence when viewed by polarized light (Congo red
stain, original magnification ×400).
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Figure 9. A small amount of amyloid deposits can be detected by placing the Congo red stained section under fluores‐
cent light (Congo red stain, original magnification ×400).
Figure 10. Congo red stain performed on frozen tissue with green birefringence (arrow) when viewed by polarized
light (Congo red stain, original magnification ×400).
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Thioflavin T is an additional sensitive but nonspecific fluorescent stain for amyloid, which is
activated by blue light to emit yellow green fluorescence staining upon binding to amyloid
[42]. This test is more sensitive than Congo red in detecting a small amount of amyloid deposits.
However, due to lack of specificity, it must be confirmed by Congo red apple green birefrin‐
gence, IF, IHC, and/or EM.
AL amyloid nephropathy may coexist with other manifestations of the monoclonal protein,
such as light-chain cast nephropathy, light-chain proximal tubulopathy, and rarely monoclo‐
nal immunoglobulin deposition disease. Any amyloid type may have coexisting other
conditions in the kidney biopsy, such as acute tubular necrosis, diabetic nephropathy, thin
basement membrane lesion, or arterionephrosclerosis.
6.2. Immunofluorescence microscopy
Immunofluorescence (IF) microscopy or immunohistochemistry is crucial for confirming the
presence and for typing of amyloid nephropathy. IF is useful for detection of amyloid derived
from Ig light and heavy chains. Amyloid deposits have a distinctive smudgy appearance of
staining (Figure 11a). Restriction for light chain, either kappa or more commonly lambda, or
for heavy-chain determents (γ or μ) must be demonstrated, in association with Congo red
positivity, for a diagnosis of AIg amyloidosis. Therefore, IF staining for kappa and lambda
should be routinely performed on all native renal biopsies. The findings of strong staining for
a monoclonal Ig light chain with negativity for Ig heavy chains is diagnostic of AL nephrop‐
athy (Figure 11a and b). About 75% of AL nephropathy cases are due to monoclonal lambda
deposits. The diagnosis of AH nephropathy is based on the presence of strong staining for a
single Ig heavy chain with negativity for kappa and lambda light chains (Figure 12). AHL
nephropathy shows intense staining for Ig heavy chain and a single Ig light chain (Figure 13a
and b).
Figure 11. AL nephropathy with smudgy mesangial, vascular, and interstitial staining for lambda (a) and negative
kappa (b) (IF, original magnification ×400).
In addition to specific staining for proteins that comprise the amyloid, amyloid deposits often
have low levels of nonspecific trapping with several reagent antibodies, including Ig and
complements (Figure 14a and b). This varies, with different reagent antibodies and different
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specimens, and is more common with AA nephropathy than AL nephropathy. The basis for
this low level of staining is not well understood, but may result from charge interaction
between the amyloid and the reagent antibodies, contamination with serum proteins, and/or
humoral reaction directed against amyloid fibrils. These low levels of nonspecific trapping
sometime render the distinction between AA nephropathy and AL/AH/AHL nephropathy
difficult. About 21% of AA nephropathy cases from a study by Nasr et al. [8] could not be
diagnosed with certainty by IF and needed confirmation of amyloid type by mass spectrom‐
etry.
Figure 12. AH nephropathy. Intense glomerular staining for IgG heavy chain. Kappa and lambda are negative (IF,
original magnification ×400).
Figure 13. AHL nephropathy. Intense glomerular, vascular and tubular basement membrane staining for IgG heavy
chain (a) and lambda light chain (b). Kappa is negative (IF, original magnification ×400).
Figure 14. Low level of non-specific staining for Immunoglobulin M (IgM) (a, arrow) and complement 3 (C3) (b, ar‐
row) in AA nephropathy (IF, original magnification ×400).
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6.3. Electron microscopy
Transmission electron microscopy (TEM) is helpful in confirming the diagnosis of amyloido‐
sis, but it is not helpful in determining the type of amyloid. At low magnification, amyloid
deposits have a characteristic cottony appearance (Figure 15) that should alert the patholo‐
gist to investigate at higher magnification the possibility of amyloidosis. At high magnifica‐
tion, amyloid is composed of randomly arranged, elongated fibrils that measure 8–12 nm in
diameter (Figure 16). Amyloid fibrils are associated with smaller, round structures, namely,
amyloid p component. The fibrils are extracellular and located near mesangial cells in
glomeruli and myocytes in the media of vessel walls in amyloid nephropathy. The amyloid
Figure 15. Extensive expansion of the mesangium by amyloid, which shows lumpy cottony appearance (arrow) on low
power electron microscopy (transmission electron microscopy (TEM), original magnification, ×5600).
Figure 16. AL nephropathy. Amyloid fibrils replacing normal mesangium. Typical amyloid fibrils are randomly ar‐
ranged, nonbranching and measure 8–12 nm in diameter (TEM, original magnification, ×14,000).
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fibrils may extend into the capillary walls and thus, foot process effacement is commonly seen
in the segments of glomerular basement membranes overlying amyloid deposits. The
podocyte cytoplasm adjacent to the amyloid deposits often shows condensation of actin
cytoskeleton. When amyloid deposits extend into the subepithelial zone, the fibrils usually
show parallel alignment (Figure 17). This is the basis for the JMS-positive feathery spikes that
may be seen by light microscopy (LM).
Figure 17. Alignment of amyloid fibrils (arrow) in the subepithelial zone of a glomerular basement membrane. This is
the basis for the JMS-positive feathery spikes that may be seen by LM (TEM, original magnification, ×5600).
6.4. Differential diagnosis
The differential diagnosis and distinction from other glomerular diseases are summarized in
Table 2. By LM, the differential diagnosis includes any disease process that induces accumu‐
lation of acellular eosinophilic material in glomeruli, blood vessels, and interstitium.
Accumulations of collagenous matrix, as in Kimmelstiel-Wilson nodules in diabetic nephrop‐
athy or sclerosis secondary to chronic immune complex glomerulonephritis or hypertensive
nephrosclerosis, usually can be readily distinguished from amyloid by routine staining. As
mentioned earlier, amyloid stains weakly with PAS and very little or negative with JMS,
whereas sclerotic matrix is strongly PAS and JMS positive. Extensive glomerular deposits
present in immune complex glomerulonephritis, fibrillary glomerulonephritis, immunotac‐
toid glomerulopathy, and collagenofibrotic glomerulopathy may mimic amyloidosis on H&E
stained sections; however, special stains, IHC, and EM demonstrate the distinctive features of
each of these diseases. The Congo red stain is then necessary to confirm the diagnosis of
amyloid nephropathy.
Light-chain deposition disease (LCDD) shares monoclonal immunoglobulin light-chain
staining with AL nephropathy, but the pattern of staining is much different. LCDD typically
has a more diffuse and regular distribution of staining that appears linear or ribbon-like along
glomerular and tubular basement membranes. The expanded mesangium also shows globular
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staining in LCDD, in contrast to AL nephropathy, which typically shows a smudgy pattern of
lambda or kappa light-chain staining with fuzzy border in the mesangium or along glomeru‐
lar basement membranes, but no ribbon-like tubular basement membrane deposits.
Differential
diagnosis
Congo red
stain
LM IF EM
Light-chain
deposition
disease
Negative  Deposition of PAS
positive 
and argyrophilic material
in mesangium with
occasional nodular
formation
Diffuse intense staining
of single light chain
(more often kappa) along
tubular and/or
glomerular basement
membranes (ribbon-like),
involving mesangium
(globular), and blood
vessels
Finely granular (punctate) or
amorphous electron dense
deposits along the inner aspect
of glomerular basement
membranes and outer aspect of
tubular basement membranes
Light- and heavy-
chain deposition
disease
Negative Deposition of PAS
positive 
and argyrophilic
material  in mesangium
with occasional nodular
formation,
more mesangial
hypercellularity
Diffuse intense staining
of single Ig heavy chain
(more often IgG) and a
single light chain along
tubular and/or
glomerular basement
membranes (ribbon-like),
involving mesangium
(globular), and blood
vessels
Finely granular (punctate) or
amorphous electron dense
deposits along the inner aspect
of glomerular basement
membranes and outer aspect of
tubular basement membranes,
occasional immune complex-
type deposits, or rarely no
electron deposits detected
Heavy-chain
deposition
disease
Negative Deposition of PAS
positive  and
argyrophilic material in
mesangium with
occasional nodular
formation,
more mesangial
hypercellularity
Diffuse intense staining
of single Ig heavy chain
(more IgG3) along
tubular and/or
glomerular basement
membranes (ribbon-like),
involving mesangium
(globular), and blood
vessels, no kappa or
lambda staining
Finely granular (punctate) or
amorphous electron dense
deposits along the inner aspect
of glomerular basement
membranes and outer aspect of
tubular basement membranes,
occasional immune complex-
type deposits, or rarely no
electron deposits detected
Fibrillary GN Negative Deposition of PAS
positive and
nonargyrophilic in
mesangium and
occasionally along
glomerular basement
membranes
Smudgy staining for IgG
(more often IgG4), C3,
kappa, and lambda in
mesangium and along
capillary loops, about
10% show restriction of
light-chain staining
Randomly arranged
nonbranching fibrils size of
12-27 nm in diameter within
mesangium, along outer aspect
of glomerular basement
membranes, and rarely along
tubular basement membranes
Immunotactoid
glomerulopathy
Negative Deposition of PAS
positive  and
nonargyrophilic in
Smudgy staining for IgG
(more often IgG1), C3,
with light chain
Microtubular or cylindrical
structure with hollow cores with
a size from 20 to 90 nm in
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Differential
diagnosis
Congo red
stain
LM IF EM
mesangium and
occasionally along
glomerular basement
membranes
restriction (more kappa),
staining in mesangium
and capillary loops
diameter, arranged in parallel
arrays, predominantly present in
mesangium and subepithelial
zone
Diabetic
nephropathy
Negative Accumulation of PAS
positive and argyrophilic
glycosylate products,
Kimmelstiel-Wilson
nodules, prominent
glomerular basement
membranes
Linear accentuation of
IgG and albumin along
glomerular and tubular
basement membranes
Diabetic fibrillosis with
branching fibrils with a size of
10–25 nm in diameter in
mesangium, thickened
glomerular basement
membranes
Collagenofibrotic
glomerulopathy
Negative Increase in mesangial
matrix, argyrophilic,
PAS  positive material
with intense blue
staining on Masson
trichrome stain
Negative staining curved and frayed, sometimes
worm-like of comma-shaped
fibers with transverse band
structure with periodicity of 43–
65 nm when sectioned
transversely
Fibronectin
glomerulopathy
Negative Mesangial matrix
accumulation of
nonargyrophilic material
with bright red staining
on Masson trichrome
stain
May have nonspecific
staining for IgG, IgM,
and C3
Granular to fibrillary
substructures with a size of 14–
16 nm in diameter
Table 2. Histologic differential diagnosis of amyloid nephropathy.
By EM, the differential diagnosis includes other renal diseases that have deposits containing
organized fibrillary or microtubular substructures, including fibrillary glomerulonephritis,
immunotactoid glomerulopathy, and collagenofibrotic glomerulopathy. Fibrillary glomeru‐
lonephritis is characterized by glomerular deposits composed of randomly arranged, non‐
branching fibrils that usually are 12–27 nm in diameter (Figure 18). The diagnosis of
amyloidosis is unlikely if fibrils are larger than 20 nm. Immunotactoid glomerulopathy has
organized microtubular substructures with hollow cores, measuring 20–90 nm (Figure 19).
Collagenofibrotic glomerulopathy shows collagen fibrils deposited predominantly in the
mesangium but sometimes can extend to subendothelial zone. The collagen fibrils appear
curved and often frayed with periodicity of 43–65 nm. In diabetic fibrillosis, the fibrils are 10–
25 nm, negative for Congo red and Thioflavin T. These fibrils tend to be shorter and more often
aligned in parallel, slightly curved, and sometimes are oriented at right angles to mesangial
cell surfaces, and may touch plasma membranes (Figure 20). Of note, the presence of diabet‐
ic fibrillosis in diabetic nephropathy does not appear to have any specific clinical connota‐
tions because a patient with this disorder behaves similarly clinically to those without fibrils
[36]. For each of the above conditions with substructure of material by EM, IF and light
microscopic appearances, and negative Congo red stain, allow distinction from amyloidosis.
Amyloid Nephropathy: A Practical Diagnostic Approach and Review on Pathogenesis
http://dx.doi.org/10.5772/64083
299
Figure 18. Fibrillary glomerulonephritis with randomly arranged nonbranching fibrils that measure 12–27 nm in diam‐
eter (TEM, original magnification, ×14,000).
Figure 19. Immunotactoid glomerulopathy. Replacement of mesangial matrix by microtubular substructures (arrow)
with hollow cores that measure 20–90 nm in diameter (TEM, original magnification, ×14, 000).
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Figure 20. Diabetic fibrillosis. Replacement of mesangial matrix by short nonbranching fibrils that measure 10–25 nm
in diameter. These fibrils tend to be more often aligned in parallel, slightly curved, and sometimes are oriented at right
angles to mesangial cell surfaces (TEM, original magnification, ×14,000).
6.5. Typing of amyloid does matter
Amyloid typing is absolutely crucial for clinical management in order to avoid misdiagnosis
and inappropriate, potentially harmful treatment, to assess prognosis and to offer genetic
counseling if relevant. The classification is based on the nature of amyloid precursor plasma
proteins. The initial step is IF, which is an important technique for AL typing. In AL nephr‐
opathy, there is restriction for either kappa or lambda light chain. In AH nephropathy, the
deposits stain only a single subclass of Ig heavy chain, whereas a single heavy-chain and a
single light-chain stain positive in AHL nephropathy. In cases where no frozen tissue is
available, IF can be performed on paraffin embedded tissue by a pronase-digested technique.
The paraffin-embedded tissue pronase-digested technique has less sensitivity than frozen
tissue IF. Thus, negative IF staining for Ig light chains or heavy chain does not completely rule
out AL nephropathy, AH nephropathy, or AHL nephropathy, as some monoclonal proteins
may be mutated and not recognized by commercial antibodies. However, a negative IF study
does typically suggest another type of amyloid nephropathy and requires further explora‐
tion by other modalities to diagnose the type of amyloid.
Current diagnostic methods, such as IHC technique using antibody-based amyloid typing,
have limited ability to detect the full spectrum of amyloid forming proteins. Although IHC
can be performed using commercially available antibodies against amyloid of the classes AL,
AH, AA, AFib, ATTR, AApo AI, and Aβ2M [10], of these antibodies, serum amyloid A (SAA)
IHC on paraffin-embedded tissue is the most extensively used and is considered the gold
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standard technique for diagnosing AA (Figure 21). AA IHC reveals a pattern of distribution
matching that seen by LM. From our study, IHC on paraffin-embedded tissue for LECT2 is
sensitive; however, it is not entirely specific for ALECT2 [41]. It is recommended that the
diagnosis of ALECT2 nephropathy should be confirmed by mass spectrometry analysis of
renal tissues when the staining pattern shows equivocal Intensity [41].
Figure 21. AA nephropathy with intense glomerular and vascular staining for SAA IHC (anti-SAA IHC, original mag‐
nification ×200).
In spite of the availability of IF and IHC, there are multiple drawbacks of these methods, such
as sensitivity and specificity of commercial antibodies that are designed against only nonmu‐
tated proteins. Mutant proteins and proteins with conformational changes might be less
reactive to commercial antibodies [39]. For example, in 7–35% of the AL nephropathy cases,
the amyloid deposits were negative for both kappa and lambda IF staining on frozen tissue [7].
Therefore, be aware that a negative staining for light- and/or heavy-chain IF does not ex‐
clude AIg nephropathy. Of note, rare cases of amyloid nephropathy show more than one type
of amyloid protein, leading to difficulty in typing. The drawbacks of these techniques may be
solved by mass spectrometry, which is discussed below.
6.6. Proteomics
The direct technique of amyloid demonstration is based on proteomic analysis using laser
microdissection/mass spectrometry (LMD/MS), which has the capability for identification of
the many different proteins [43]. This technique has a high sensitivity and specificity and solves
many of the problems presented by other techniques [44].
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LMD/MS has proved to be useful to determine the nature and type of the amyloid precursor
protein in cases that could not be typed by routine IHC panels [45, 46]. The major advantage
of LMD/MS over conventional IHC techniques in typing of amyloid is that LMD/MS is a single
test that can identify and type the amyloid protein, in contrast to IHC that may require several
antibodies staining multiple sections [47]. Furthermore, LMD/MS is performed from paraf‐
fin-embedded tissue and requires no special treatment. The common indications for LMD/MS
in amyloid nephropathy include amyloid type confirmation, insufficient tissue sample for IF
or IHC studies but with remaining tissue in paraffin block, difficult cases on routine renal
biopsy studies such as heavy-chain amyloidosis and familial and hereditary forms of amyloi‐
dosis [17, 48, 49]. The diagnosis of amyloidosis at the proteomic level using LMD/MS is purely
based on the presence of large spectra of proteins, which have amyloidogenic properties, in
addition to apolipoprotein E (Apo E) and SAP that are commonly present in all types of
amyloid [40]. Therefore, in AA nephropathy, large spectra numbers of serum amyloid-
associated protein along with Apo E and SAP are present. In contrast, in ALECT2 and AGel
nephropathy, large spectra numbers of LECT2 and gelsolin are present along with Apo E and
SAP.
LMD/MS has been very helpful in achieving amyloid typing from formalin-fixed paraffin-
embedded tissue. LMD/MS has also been critical for the typing of cases with limited anti‐
body reactivity and in the discovery of new protein types of amyloid. From a study by Said et
al., the type of amyloid in 16% of amyloid nephropathy cases could not have been typed
without LMD/MS [8]. In spite of these major advantages, LMD/MS also has a few draw‐
backs. As mentioned above, identification of amyloid proteins is purely based on the pres‐
ence of large spectra for proteins, which have amyloidogenic properties within the analyzed
sample. In a case of focal amyloidosis, a small amount of amyloid deposit may be obscured by
Apo E, SAP, and various serum proteins. Furthermore, the observed peptide fragmentation
data must be matched to known protein sequences that are available in the public data base,
and thus, unknown protein sequences due to certain germ line polymorphisms or somatic
mutations, may not be identified. Despite these drawbacks, the number of cases of amyloid
with undetermined type has markedly decreased with use of this technique to 7%, with 3% of
the sample insufficient for analysis [7, 8, 50]
6.7. Treatment and prognosis
The goal of current treatment approaches for AIg nephropathy is to eradicate the clone of
plasma cells that produce amyloidogenic monoclonal light chains, Ig heavy chain, and Ig heavy
and light chain. Patients with AIg nephropathy are usually treated with chemotherapeutic
regimens appropriate for B-cell or plasma cell neoplasm. Melphalan-dexamethasone-borte‐
zomib is commonly used as frontline regimen for patients with Stages I and II cardiac
involvement [51]. Patients with Stage III cardiac involvement or advanced chronic kidney
disease (CKD) patients are generally treated with cyclophosphamide-bortezomib-dexametha‐
sone [51, 52], which showed overall 81.4% hematologic response [53]. High-dose intrave‐
nous melphalan followed by autologous stem cell transplantation (HDM/ASCT) to support
bone marrow recovery has emerged as the most likely to eradicate the clonal plasma cells [39].
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Experiences from several treatment centers has suggested that 25–50% of patients who
undergo such treatment have complete hematologic response, indicating that there is no
evidence of ongoing production of monoclonal light chains, Ig heavy chain, or Ig heavy chain
and light chain [52–54]. HDM/ASCT is generally offered to patients with Stages I or II cardiac
involvement patients who have glomerular filtration rate (GFR) ≥ 30 mL/min in the absence
of advanced other organ involvement [54–56].
Treatment of the underlying chronic inflammatory diseases, such as immunosuppressive
agents for rheumatoid arthritis and inflammatory bowel diseases is beneficial in patients with
AA nephropathy. The basis of modern treatment in AA nephropathy is still reduction of SAA
production. Additionally, steroids and cytotoxic drugs, treatment with monoclonal antibod‐
ies against cytokines, particularly tumor necrotic factors (TNF) and interleukin-6 (IL-6), are
effective in many cases [57]. This approach of treatment is targeted not only at amyloid fibrils
themselves but also at messengers in the acute-phase response. Other therapies, such as
antisense oligonucleotides, have been suggested to specifically lower the expression of SAA
in the liver [57]. AA nephropathy caused by familial Mediterranean fever responds to
colchicine [58]. In familial amyloidosis, including AFib, ATTR, and AApo AI, in which the
liver is the source of precursor protein, patients are treated with liver transplantation [57]. A
novel drug, R-1-[6-[R-2carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic
acid is a competitive inhibitor of SAP binding to amyloid fibrils [59, 60]. This palindromic
compound also cross-links and dimerizes SAP molecules, leading to their very rapid clear‐
ance by the liver, and hence produces a marked reduction in human SAP in the circulation [61].
This mechanism of drug action potently removes SAP from the deposits of amyloid in human
tissue and may provide a new therapeutic approach to AA amyloidosis and diseases associ‐
ated with local amyloid deposition, including Alzheimer’s disease [61].
The prognosis for patients with AL nephropathy is generally poor and depends on systemic
organ involvement, but survival can be prolonged with treatment [62, 63]. Patients with AL
nephropathy have a median overall survival of 1–2 years [62, 63]. Patients with AA nephrop‐
athy have a better prognosis than those with AL nephropathy with the median survival varies
between 2 and 10 years [13, 64]. In AL nephropathy and AA nephropathy, cardiac involve‐
ment is an independent negative predictive factor of patient survival [13]. Patients with AA,
AH, AHL, AFib, and ALECT2 nephropathy have longer overall survival compared with AL
nephropathy, largely because of a lower rate of cardiac involvement [13, 65, 66]. The mean
survival for AFib is 15 years [10], and the median survival for ALECT nephropathy is
62 months [66].
In AL nephropathy, kidney transplantation is ideally performed after production of amyloi‐
dogenic light-chain proteins has been eradicated. Kidney transplantation for systemic AL
patients has a relative good outcome with 1- and 5-year patient survival of 75% and 67% and
median graft survival of 5.8 years [67–69]. However, amyloidosis may recur in kidney
transplants, depending on the amyloid type and progression of the underlying disease. In a
large series from the UK, among 246 patients with AL nephropathy with renal failure, only
10% received kidney transplants [69], and of these, amyloidosis recurred in 28%; however, no
graft was lost due to recurrent AL amyloidosis [67]. Patient survival was best among pa‐
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tients who had achieved partial remission before kidney transplantation (8.9 years). In a French
series of 59 recipients with AA amyloidosis, recurrence was documented in 14% at a median
of 10 years posttransplant and was often associated with nephrotic range proteinuria [70].
Among 10 recipients with hereditary AFib amyloidosis who received kidney transplantation
only, recurrent AFib amyloidosis was detected in 70% and median graft survival was
7.3 years [69]. In contrast, no recurrence was detected in the nine patients who received
combined kidney and liver transplantation, but the mean renal graft survival was 6.4 years
[62]. Hereditary AApo I amyloidosis has recurred in 30% who received kidney transplanta‐
tion only, and of these, one graft was lost to recurrent AApo I amyloidosis [68]. There is no
effective therapy for ALECT2 nephropathy [37]. Because the precursor protein in ALECT2 is
nonmutant, liver transplantation is likely ineffective [26]. Kidney transplantation has been
suggested as a treatment option for ALECT2 nephropathy patients with advanced renal
failure [35]. Although the disease may recur in about 20% of allografts, no graft was lost to
recurrent ALECT2 nephropathy [69]. Possible future therapies for ALECT2 nephropathy
include reducing the supply of LECT2 (e.g., inhibiting the Wnt/β-catenin signal pathway),
inhibiting amyloid fibril formation by blocking the binding of glycoaminoglycans to amy‐
loid fibrils, promoting clearance of amyloid by immunotherapy, and promoting amyloid
regression by SAP-targeted therapy.
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